tbuckley/cabot-search huggingface dataset:
BOOK REVIEWS
Authors: B. D. CHESON
Journal: JNCI Journal of the National Cancer Institute (1988)

BOOK REVIEWS Get access Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. Robert Peter Gale, Kanti R. Rai, eds. New York: Liss, 1987, 452 pp. $80.00. BRUCE D. CHESON BRUCE D. CHESON Clinical Investigations Branch, Division of Cancer Treatment, National Cancer InstituteLandow Building, Room 4A18, Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 1, 2 March 1988, Pages 65–66, https://doi.org/10.1093/jnci/80.1.65 Published: 02 March 1988
Sri Lankan refugees are not at risk of persecution
Journal: BMJ (1997)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Sri Lankan refugees are not at risk of persecution Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Surgical Measures for Coronary Heart Disease
Authors: Eldred D. Mundth, W. Gerald Austen
Journal: New England Journal of Medicine (1975)

Postoperative Myocardial InfarctionElectrocardiographic evidence of acute myocardial infarction early after operation has been reported in 5 to 40 per cent of patients undergoing elective coronary-artery bypass graft procedures (Table 6).44,45,49–52,70 71 72 73 74 75 76 Since a frequently invoked indication for bypass graft is prevention of myocardial infarction, it is important to consider the actual incidence of postoperative myocardial infarction, the risk factors that contribute to it and the clinical importance that it has. Although there probably is no completely definitive and accurate method of diagnosis of postoperative myocardial infarction after bypass graft procedures, electrocardiographic evidence of new and persistent . . .
Evolution of the randomized controlled trial (RCT) in oncology over three decades
Authors: C. M. Booth, D. W. Cescon, L. Wang, I. F. Tannock, M. K. Krzyzanowska
Journal: Journal of Clinical Oncology (2007)

6515 Background: The RCT is the gold standard for establishing new therapies in oncology. Here we document changes with time in design, results, author conclusions and sponsorship. Methods: Reports of RCTs evaluating systemic therapy for breast, colorectal (CRC) and non-small cell lung cancer (NSCLC) published 1975–2004 in 6 major journals were reviewed. Two authors independently abstracted data regarding trial design, effect size and author conclusions. Author conclusions were assigned a score from 1 to 7: 4/7 for a neutral statement, 7/7 and 1/7 for strong endorsement of experimental and control arm respectively. For each study the effect size for the primary endpoint was converted to a summary measure: hazard ratio [HR] for survival endpoints and relative risk [RR] for response rate. Descriptive statistics were used to analyze trends over time. Results: 326 eligible RCTs were included (48% breast, 24% CRC, 28% NSCLC). There was a significant increase in the number and size of RCTs (see Table ). Median rate of accrual increased from 7 patients/month in 1975–84 to 14 patients/month in 1995–2004 (p&lt;0.001). There was an increase in multicenter (55 to 95%, p&lt;0.001), international trials (26 to 52%, p&lt;0.001) and for-profit sponsorship over time (6 to 57%, p&lt;0.001). There was increasing use of survival (13 to 48%,) and decreasing use of response rate (32 to 14%) as primary endpoint (p&lt;0.001). Authors have become more likely to strongly endorse the experimental arm despite no change in effect size over time (p=0.005). Studies sponsored by for-profit organizations were more likely to strongly endorse the experimental agent than studies not sponsored by for-profit groups (median author score 6/7 vs. 4/7, p&lt;0.001). Conclusions: RCTs in oncology have become more common, larger, and are more likely to be sponsored by industry. Authors of modern RCTs are more likely to strongly endorse novel therapies despite no increase in the relative benefit of interventions. For-profit sponsorship is associated with stronger endorsement of the experimental arm. No significant financial relationships to disclose. [Table: see text]
Associations between county-level surgeon density and colorectal cancer (CRC) mortality.
Authors: J. S. Albarrak, M. Y. Ho, W. Y. Cheung
Journal: Journal of Clinical Oncology (2011)

511 Background: Strong associations between surgeon procedure volumes and patient outcomes have been observed for many types of cancers. Whether surgeon density in a population has a similar impact on cancer outcomes is unclear. Our aims were to 1) explore the effect of US county-level surgeon density on CRC mortality and on annual changes in death, 2) compare the relative importance of colorectal surgeon (CS) versus general surgeon (GS) density on these CRC outcomes, and 3) identify other county characteristics associated with reduced mortality. Methods: Using county-level data from the Area Resource File, US Census and National Cancer Institute, we developed multivariate regression models to determine the effect of a) CS and b) GS on overall CRC mortality and changes in death between 2002 and 2006, while controlling for CRC incidence, county demographics and other socioeconomic factors. Results: A total of 1,187 US counties were included: mean CRC incidence and death rates were 64.9 and 19.9, respectively; 57% were metropolitan and 43% were rural counties; mean CS and GS densities were 1.23 and 1.94 per 100,000 people, respectively. When compared to counties with no CS and no GS, those with at least of one of these surgeons had a statistically significant decrease in CRC-specific mortality (beta coefficients were -0.035 and -0.051 for CS and GS, respectively; p=0.014). Increasing the county-level density of surgeons improved outcomes, but increasing it beyond 8 CS or 12 GS per 100,000 people did not continue to result in significant reductions in CRC mortality. Similar associations between surgeon density and annual changes in CRC-related death were observed. Counties with a high proportion of Medicare enrollees also showed increased CRC mortality. Conclusions: The presence of CS and GS at the county level is each associated with lower mortality from CRC. However, there appears to be a ceiling effect at which point further increases in their density do not produce continued improvements in CRC outcomes. A balanced strategy of allocating healthcare resources and distributing the surgical workforce evenly across all counties will likely offer the most substantial population-based improvements in CRC mortality. No significant financial relationships to disclose.
Burning Faith
Authors: Michael Wynn
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National Health Service
Authors: G. H. Gibbens
Journal: BMJ (1948)

<b>Objective:</b> To investigate the effects of Catechol-o-methyltransferase (<i>COMT</i>) Val158Met (rs4680) variant on Default Mode Network (DMN) integrity and brain atrophy rates in Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI). <b>Background:</b> AD is a neurodegenerative disorder, usually preceded by MCI. Many genetic factors have contributed to disease risk. Val158Met variant of <i>COMT</i> is one of them and associated with AD severity in several ethnic groups. It is also related to disorders like schizophrenia and is associated with psychosis development in AD. DMN is one of the first functional brain networks affected by AD and its abnormalities are related to disease severity. Age and disease related increase and decrease in connectivity are observed in anterior DMN (aDMN) and posterior DMN (pDMN), respectively. Thus, we investigated the effects of rs4680 on DMN connectivity and brain atrophy rates as measures of dysconnectivity and atrophy, respectively. <b>Design/Methods:</b> We used 526 AD and MCI subjects of Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. Whole Genome Sequencing 2.5Million Single Nucleotide Polymorphism data was used to extract subjects’ genotypes. We used Boundary Shift Integral (BSI), and Symmetrically Normalized Tensor Based Morphometry (TBM-SyN) for atrophy. Region-to-voxel (RV) correlation was used for aDMN and pDMN integrity, avoiding analysis artifacts related to variable temporal signal-to-noise in lateral hemispheric regions. All data were analyzed using SPSS v18, and adjusted for age, sex, handedness, education and APOE genotype. Results with p-value&lt;0.05 were reported. <b>Results:</b> Val158Met was not associated with significant differences of aDMN and pDMN RVs, but it was associated with more negative TBM-SyN values (p=0.004) and greater BSI values of ventricles (p=0.008). <b>Conclusions:</b><i>COMT</i> Val158Met variant is associated with greater atrophy in MCI and AD patients as indicated by TBM-SyN and BSI changes, but it does not affect aDMN and pDMN integrity. Further studies in other brain networks is suggested. <b>Disclosure:</b> Dr. Abdolalizadeh has nothing to disclose. Dr. Abbasi has nothing to disclose. Dr. Mohajer has nothing to disclose.
Erratum
Journal: BMJ (1898)

DEFECTIVE CHILDRBN.M.D.LoND. asks for information as to a home for an epileptic boy, aged 14, who is suffering from arrested mental development.It is not a case of imbecility.and there has been a slow, steady improvement in the men- tal condition for some years past.A small sum weekly or monthly could be paid.*** We may refar our correspondent to the abstract of the Report of the Departmental Committee on Defective and Epileptic Children pub- lished in the BRITISH MEDICAL JOURNAL of March 5th, p. 651.With regard to the case mentioned, assuming that the boy lives in London, the parents should place him in one of the London School Board special classes for backward and defective children.Mrs.
Guidelines for management of asthma in adults: I--Chronic persistent asthma. Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign.
Journal: BMJ (1990)

Treatment with short course of oral steroids Short courses of oral steroids may be needed to control exacerbations of asthma at any step.Indications are: * Symptoms and peak expiratory flow get progressively worse each day * Peak expiratory flow falls below 60% of patient's best result * Sleep is disturbed by asthma * Morning symptoms persist until midday * Maximum treatment not including oral steroids does not work * Emergency nebuliser or injected bronchodilators are needed Give patients prednisolone 30-60 mg daily (60 mg if they are already taking oral steroids) until two days after full recovery, when the drug may be stopped or the dose tapered.If arranged beforehand short courses oforal steroids may be started on the patient's initiative according to written guidance.
GI Surgery
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lung tomography in cancer patients. Full-lung tomograms in screening for pulmonary metastases
Authors: W. F. Sindelar
Journal: JAMA (1978)

In a retrospective study of the cases of 415 patients with various malignant neoplasms, full-lung tomography and conventional chest roentgenography were compared for accuracy in the detection of pulmonary metastases. Sufficient information was available on 410 patients to permit confirmation as to whether pulmonary metastases were present at the time of screening chest roentgenographic and tomographic examinations. On screening by routine chest roentgenography, metastases were detected in 36 patients, 66.7% of the total with confirmed metastatic disease. Screening by full-lung tomography identified metastases in 51 (94.4%). Fifteen patients with normal chest roentgenograms had metastatic lesions on tomograms. Metastases were detected in 8.8% by chest roentgenograms and in 12.4% by tomograms in a population of cancer patients with a 13.2% incidence of pathologically confirmed metastatic lesions. (<i>JAMA</i>240:2060-2063, 1978)
Specific Drugs Urged For CNS Infections
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.
Authors: Farhad Ravandi, Jorge Cortes, Stefan Faderl, Susan O'Brien, Guillermo Garcia-Manero, Srdan Verstovsek, Marcos de Lima, Sherry Pierce, Mark Brandt, Gautam Borthakur, Alessandra Ferrajoli, William G. Wierda, Charles A Koller, Hagop M. Kantarjian
Journal: Blood (2009)
The Croonian Lectures on the Relationship between Chemical Structure and Physiological Action
Authors: T. L. Brunton
Journal: BMJ (1889)

ing to finish his work in a few seconds, to spend minutes, and even hours, in doing operations carefully and thoroughly.They have thus not only made patients more ready to submit to surgical interference, but they have enabled the surgeon to attempt and perform with success operations which would formerly have been impossible.Antiseptics.-Theintroduction of antiseptics has greatly less- ened the spread of infectious diseases, and it has diminished the risk from surgical operations to an extent that is almost incredible.
Downregulation of Mpl Marks the Transition to Lymphoid-Primed Multipotent Progenitors with Gradual Loss of Granulocyte-Monocyte Potential.
Authors: Sidinh Luc, Kristina Anderson, Ms Shabnam Kharazi, Natalija Buza-Vidas, Charlotta Boiers, Christina T. Jensen, Zhi Ma, Mrs Lilian Wittman, Sten Eirik W. Jacobsen
Journal: Blood (2007)
Podocyte Aging: Why and How Getting Old Matters
Authors: Stuart Shankland, Yuliang Wang, Andrey Shaw, Joshua Vaughan, Jeffrey Pippin, Oliver Wessely
Journal: Journal of the American Society of Nephrology (2021)

The effects of healthy aging on the kidney, and how these effects intersect with superimposed diseases, are highly relevant in the context of the population's increasing longevity. Age-associated changes to podocytes, which are terminally differentiated glomerular epithelial cells, adversely affect kidney health. This review discusses the molecular and cellular mechanisms underlying podocyte aging, how these mechanisms might be augmented by disease in the aged kidney, and approaches to mitigate progressive damage to podocytes. Furthermore, we address how biologic pathways such as those associated with cellular growth confound aging in humans and rodents.
Synopsis of Medical Parasitology
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Table 1
Authors: Jessica Huston, Evan Brittain
Journal: JAMA Cardiology (2020)

Representatives of the Global Familial Hypercholesterolemia Community; Katherine A. Wilemon; Jasmine Patel, MPH; Carlos Aguilar-Salinas, MD; Catherine D. Ahmed, MBA; Mutaz Alkhnifsawi, MD; Wael Almahmeed, MD; Rodrigo Alonso, MD; Khalid Al-Rasadi, MD; Lina Badimon, PhD; Luz M. Bernal, PhD, MSc; Martin P. Bogsrud, MD, PhD; Lynne T. Braun, PhD, CNP; Liam Brunham, MD, PhD; Alberico L. Catapano, MD, PhD; Kristyna Čillíková; Pablo Corral, MD; Regina Cuevas; Joep C. Defesche, PhD; Olivier S. Descamps, MD, PhD; Sarah de Ferranti, MD, MPH; Jean-Luc Eiselé, PhD, MSc; Gerardo Elikir, MD; Emanuela Folco, PhD; Tomas Freiberger, MD, PhD; Francesco Fuggetta, BA; Isabel M. Gaspar, MD; Ákos G. Gesztes, PharmD; Urh Grošelj, MD, PhD; Ian Hamilton-Craig, MBBS, PhD; Gabriele Hanauer-Mader; Mariko Harada-Shiba, MD, PhD; Gloria Hastings; G. Kees Hovingh, MD, PhD; Maria C. Izar, MD, PhD; Allison Jamison, MBA; Gunnar N. Karlsson; Meral Kayikçioğlu, MD; Sue Koob, MPA; Masahiro Koseki, MD, PhD; Stacey Lane, JD; Marcos M. Lima-Martinez, MD; Greizy López, PhD; Tania L. Martinez; David Marais, MD; Letrillart Marion; Pedro Mata, MD; Inese Maurina; Diana Maxwell; Roopa Mehta, MD; George A. Mensah, MD; André R. Miserez, MD; Dermot Neely, MD; Stephen J. Nicholls, MBBS, PhD; Atsushi Nohara, MD, PhD; Børge G. Nordestgaard, MD, DMSc; Leiv Ose, MD, PhD; Athanasios Pallidis; Jing Pang, PhD; Jules Payne; Amy L. Peterson, MD; Monica P. Popescu; Raman Puri, MD; Kausik K. Ray, MD; Ashraf Reda, MD; Tiziana Sampietro, MD, PhD; Raul D. Santos, MD; Inge Schalkers, PhD; Laura Schreier, PhD; Michael D. Shapiro, DO; Eric Sijbrands, MD, PhD; Daniel Soffer, MD; Claudia Stefanutti, MD, PhD; Mario Stoll, MD; Rody G. Sy, MD; Martha L. Tamayo, MD, MSc; Myra K. Tilney, MD, MBA; Lale Tokgözoğlu, MD; Brian Tomlinson, MD, BSc; Antonio J. Vallejo-Vaz, MD, PhD; Alejandra Vazquez-Cárdenas, MD, PhD; Patrícia Vieira de Luca, MSc; David S. Wald, MD; Gerald F. Watts, DSc, PhD; Nanette K. Wenger, MD; Michaela Wolf; David Wood, MD; Aram Zegerius; Thomas A. Gaziano, MD, MSc; Samuel S. Gidding, MD
Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib.
Authors: Mona Lisa Alattar, Hagop Kantarjian, Mark J. Levis, Mary Ann Richie, Naval Guastad Daver, Guillermo Garcia-Manero, Stefan Faderl, Gautam Borthakur, Jan Andreas Burger, Tapan M. Kadia, Michael Richard Grunwald, Sara Dellasala, Jorge E. Cortes, Farhad Ravandi
Journal: Journal of Clinical Oncology (2012)

24 Background: Outcome of patients with relapsed acute myeloid leukemia (AML) with FLT3-ITD mutation is poor. Elevated FLT3 ligand levels (FL) secondary to cytotoxic chemotherapy is a putative mechanism of resistance to the FLT3 kinase inhibitors. We hypothesized that FL levels will be lower when combining sorafenib with less intensive therapy such as 5-Azacytidine (5-Aza). This study was conducted to evaluate the efficacy and tolerability of the combination of sorafenib and 5-Aza in patients with refractory or relapsed AML with FLT3-ITD mutation. Methods: Patients were eligible if they had relapsed or refractory AML and were 18 years of age or older. They received 5-Aza 75 mg/m 2 IV daily x 7 days and sorafenib 400 mg PO BID continuously; cycles were repeated in approximately one month intervals. Results: 38 patients with AML with a median age of 60 years (range, 24-87) were enrolled. 4 were inevaluable as they never received therapy or discontinued it before response assessment. FLT-3-ITD was detected in 30 (88%) patients. They had received a median of 2 prior treatments (range, 0-6); 13 (38%) had received ≥ 3 prior regimens and 8 had failed prior FLT3 kinase inhibitor. Response rate was 41%, including 6 (17%) with CRi, 4 (12) with CRp, 3 (9%) with CR, and 1(3%) PR. The median time to achieving CR/CRi was 2 cycles (Range, 1-6) and the median duration of CR/CRi was 3 months (Range, 1–12). Conclusions: Combination of 5-Aza and sorafenib is effective for patients with relapsed AML with FLT-3-ITD mutation.